Neratinib for HER2-positive breast cancer with an overlooked option

Positive human epidermal growth factor receptor 2 (HER2) expression is associated with an increased risk of metastases especially those to the brain in patients with advanced breast cancer (BC). Neratinib as a tyrosine kinase inhibitor can prevent the transduction of HER1, HER2 and HER4 signaling pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Liting, Shao, Weiwei, Zhou, Chenfei, Yang, Hui, Yang, Liu, Cai, Qu, Wang, Junqing, Shi, Yan, Huang, Lei, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559443/
https://www.ncbi.nlm.nih.gov/pubmed/37803271
http://dx.doi.org/10.1186/s10020-023-00736-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559443/
https://www.ncbi.nlm.nih.gov/pubmed/37803271
http://dx.doi.org/10.1186/s10020-023-00736-0

Ejemplares similares